Search Results - "Herrak, P"

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    Zoledronic acid protects from local and systemic bone loss in TNF-mediated arthritis

    Zoledronic acid protects from local and systemic bone loss in TNF-mediated arthritis by Zwerina, J, Herrak, P, Goertz, B, Hayer, S, Redlich, K, Reiter, E, Gasser, J, Bergmeister, H, Kollias, G, Smolen, JS, Schett, G

    Published in Arthritis research & therapy (2004)
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    Zoledronic acid protects from local and systemic bone loss in tumor necrosis factor-mediated arthritis

    Zoledronic acid protects from local and systemic bone loss in tumor necrosis factor-mediated arthritis by Redlich, K, Herrak, P, Görtz, B, Hayer, S, Reiter, E, Gasser, J, Bergmeister, H, Kollias, G, Smolen, JS, Schett, G

    Published in Arthritis research & therapy (2004)
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor–mediated arthritis

    Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor–mediated arthritis by Herrak, Petra, Görtz, Birgit, Hayer, Silvia, Redlich, Kurt, Reiter, Erika, Gasser, Jürg, Bergmeister, Helga, Kollias, Giorgos, Smolen, Josef S., Schett, Georg

    Published in Arthritis and rheumatism (01-07-2004)
    “…Objective Increased osteoclast activity is a key factor in bone loss in rheumatoid arthritis (RA). This suggests that osteoclast‐targeted therapies could…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: